SRR1370473
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.422
- PANCREAS_BETA_CELLS+0.393
- COAGULATION+0.374
- INFLAMMATORY_RESPONSE+0.305
- ALLOGRAFT_REJECTION+0.248
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.238
- IL6_JAK_STAT3_SIGNALING+0.237
- APICAL_SURFACE+0.209
- KRAS_SIGNALING_UP+0.195
- SPERMATOGENESIS+0.149
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.614
- MYC_TARGETS_V1-0.608
- MYC_TARGETS_V2-0.599
- DNA_REPAIR-0.547
- UNFOLDED_PROTEIN_RESPONSE-0.507
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.494
- MTORC1_SIGNALING-0.483
- PROTEIN_SECRETION-0.441
- CHOLESTEROL_HOMEOSTASIS-0.422
- PI3K_AKT_MTOR_SIGNALING-0.415
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1343197 | GTEX | — | 0.968 |
| 2 | SRR1341057 | GTEX | — | 0.961 |
| 3 | SJEPD001523_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.959 |
| 4 | SRR1418604 | GTEX | — | 0.958 |
| 5 | SRR1444559 | GTEX | — | 0.958 |
| 6 | SRR1486475 | GTEX | — | 0.957 |
| 7 | SRR1476614 | GTEX | — | 0.956 |
| 8 | SRR1389348 | GTEX | — | 0.955 |
| 9 | SRR819793 | GTEX | — | 0.954 |
| 10 | SRR1455305 | GTEX | — | 0.953 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.422 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.393 | Cobimetinib | — uncovered |
| COAGULATION | 0.374 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.305 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.248 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.238 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.237 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.209 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.195 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.149 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.139 | Idelalisib | — uncovered |
| COMPLEMENT | 0.108 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.071 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.065 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.056 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.054 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.037 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.031 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.026 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.015 | Idelalisib | — uncovered |